Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, June 24th.

Aethlon Medical Price Performance

AEMD stock opened at $0.35 on Thursday. The firm has a market cap of $4.83 million, a PE ratio of -0.07 and a beta of 1.65. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $2.93. The firm has a 50 day simple moving average of $0.40 and a 200 day simple moving average of $0.92.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the business earned ($1.30) EPS. As a group, sell-side analysts expect that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.